Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Short-term Investments (2021 - 2025)

Aligos Therapeutics' Short-term Investments history spans 5 years, with the latest figure at $110000.0 for Q4 2025.

  • For Q4 2025, Short-term Investments rose 10.0% year-over-year to $110000.0; the TTM value through Dec 2025 reached $110000.0, up 10.0%, while the annual FY2025 figure was $110000.0, 10.0% up from the prior year.
  • Short-term Investments reached $110000.0 in Q4 2025 per ALGS's latest filing, roughly flat from $110000.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $88.2 million in Q2 2022 to a low of $42000.0 in Q2 2023.
  • Average Short-term Investments over 5 years is $14.4 million, with a median of $190000.0 recorded in 2021.
  • Peak YoY movement for Short-term Investments: plummeted 99.95% in 2023, then soared 117657.14% in 2024.
  • A 5-year view of Short-term Investments shows it stood at $164000.0 in 2021, then tumbled by 39.02% to $100000.0 in 2022, then changed by 0.0% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024, then increased by 10.0% to $110000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Short-term Investments are $110000.0 (Q4 2025), $110000.0 (Q3 2025), and $110000.0 (Q2 2025).